Information Provided By:
Fly News Breaks for November 8, 2019
Nov 8, 2019 | 06:32 EDT
JMP Securities analyst Jason Butler lowered his price target on Adamas Pharmaceuticals to $16 after its Q3 earnings miss driven by higher than expected SG&A expenses and slightly-below-consensus GOCOVRI sales. The analyst still keeps his Outperform rating on confidence that the "refreshed" management team can reinvigorate the GOCOVRI launch but lowers his projected peak penetration sales to $250M from $550M. Butler is also removing the ADS-4101 from his model until there is more clarity on its path forward.
News For ADMS From the Last 2 Days
There are no results for your query ADMS